AEON Biopharma (AEON) to Release Quarterly Earnings on Wednesday
by Doug Wharley · The Cerbat GemAEON Biopharma (NASDAQ:AEON – Get Free Report) is expected to release its results before the market opens on Wednesday, April 1st. Analysts expect AEON Biopharma to post earnings of ($0.17) per share for the quarter.
AEON Biopharma Price Performance
AEON opened at $0.99 on Tuesday. The firm has a market cap of $11.71 million, a P/E ratio of 5.50 and a beta of 0.72. AEON Biopharma has a 1-year low of $0.38 and a 1-year high of $1.45. The company has a 50 day simple moving average of $1.12 and a two-hundred day simple moving average of $1.00.
Institutional Inflows and Outflows
An institutional investor recently raised its position in AEON Biopharma stock. Geode Capital Management LLC boosted its holdings in AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 27.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the quarter. Geode Capital Management LLC owned approximately 0.51% of AEON Biopharma worth $66,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.78% of the company’s stock.
AEON Biopharma Company Profile
AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.
Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.